Federal Trade Commission Reaches Record $1.2 Billion Proposed “Pay for Delay” Settlement with Cephalon and Injunctive Relief Restricting Future Similar Settlements of Patent Infringement Cases* Last week, on the eve of trial, the Federal Trade Commission (“FTC”) reached a proposed settlement in its civil antitrust lawsuit against Cephalon, Inc. (“Cephalon”). The FTC challenged Cephalon’s prior settlement of patent infringement litigation brought against generic drug makers seeking to enter the market with a copy of Cephalon’s blockbuster sleep-disorder drug Provigil. The long-running antitrust case began in 2008 when the FTC sued Cephalon, arguing that there was no rational economic basis for Cephalon’s simultaneous settlement of its patent infringement case and entry into separate business
Share on
|
|
The US FTC reaches a record $1.2 billion proposed pay-for-delay settlement and injunctive relief restricting future similar settlements of patent infringement cases (Cephalon)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
